{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:15:40Z","timestamp":1769109340966,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"EU-FP7 PHARVAT","award":["FP7-HEALTH-2007- 223226"],"award-info":[{"award-number":["FP7-HEALTH-2007- 223226"]}]},{"name":"EU-FP7 project TRANSVAC","award":["EU-FP7 project TRANSVACFP7-INFRASTRUCTURES-2008-228403"],"award-info":[{"award-number":["EU-FP7 project TRANSVACFP7-INFRASTRUCTURES-2008-228403"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12865-018-0245-0","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T12:36:44Z","timestamp":1517402204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation"],"prefix":"10.1186","volume":"19","author":[{"given":"Sumera Y.","family":"Younis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Barnier-Quer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Heuking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Sommandas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"vd.Werff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Friede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Kocken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Collin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Remarque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"issue":"11","key":"245_CR1","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.4049\/jimmunol.153.11.4948","volume":"153","author":"Y Kawano","year":"1994","unstructured":"Kawano Y, Noma T, Yata J. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol. 1994;153(11):4948\u201358.","journal-title":"J Immunol"},{"issue":"4","key":"245_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.175.4.973","volume":"175","author":"JM Purkerson","year":"1992","unstructured":"Purkerson JM, Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J Exp Med. 1992;175(4):973\u201382.","journal-title":"J Exp Med"},{"issue":"5","key":"245_CR3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.4049\/jimmunol.162.5.2812","volume":"162","author":"C Mizoguchi","year":"1999","unstructured":"Mizoguchi C, et al. IL-5 induces IgG1 isotype switch recombination in mouse CD38-activated sIgD-positive B lymphocytes. J Immunol. 1999;162(5):2812\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"245_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0022-1759(98)00015-5","volume":"212","author":"RM Martin","year":"1998","unstructured":"Martin RM, Brady JL, Lew AM. The need for IgG2c specific antiserum when isotyping antibodies from C57BL\/6 and NOD mice. J Immunol Methods. 1998;212(2):187\u201392.","journal-title":"J Immunol Methods"},{"issue":"2","key":"245_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/BF00395856","volume":"29","author":"E Jouvin-Marche","year":"1989","unstructured":"Jouvin-Marche E, et al. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics. 1989;29(2):92\u20137.","journal-title":"Immunogenetics"},{"issue":"48","key":"245_CR6","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1016\/j.vaccine.2008.08.055","volume":"26","author":"BW Faber","year":"2008","unstructured":"Faber BW, et al. Production, quality control, stability and pharmacotoxicity of cGMP-produced plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia Pastoris. Vaccine. 2008;26(48):6143\u201350.","journal-title":"Vaccine"},{"issue":"2","key":"245_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pt.2007.12.002","volume":"24","author":"EJ Remarque","year":"2008","unstructured":"Remarque EJ, et al. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008;24(2):74\u201384.","journal-title":"Trends Parasitol"},{"issue":"3","key":"245_CR8","first-page":"347","volume":"71","author":"HY Lei","year":"1990","unstructured":"Lei HY, Lee SC, Yu CK. Distinct regulation of humoral and cellular immunities to hepatitis B surface antigen. Immunology. 1990;71(3):347\u201351.","journal-title":"Immunology"},{"issue":"7","key":"245_CR9","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1128\/IAI.68.7.3854-3860.2000","volume":"68","author":"A Tanghe","year":"2000","unstructured":"Tanghe A, et al. Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect Immun. 2000;68(7):3854\u201360.","journal-title":"Infect Immun"},{"issue":"24","key":"245_CR10","doi-asserted-by":"publisher","first-page":"7739","DOI":"10.1128\/AEM.01965-09","volume":"75","author":"NA Parlane","year":"2009","unstructured":"Parlane NA, et al. Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents. Appl Environ Microbiol. 2009;75(24):7739\u201344.","journal-title":"Appl Environ Microbiol"},{"issue":"5","key":"245_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","volume":"82","author":"EB Lindblad","year":"2004","unstructured":"Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol. 2004;82(5):497\u2013505.","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"245_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/sj.clpt.6100402","volume":"82","author":"DT O'Hagan","year":"2007","unstructured":"O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther. 2007;82(6):740\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"245_CR13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","volume":"146","author":"CR Kensil","year":"1991","unstructured":"Kensil CR, et al. Separation and characterization of saponins with adjuvant activity from Quillaja Saponaria Molina cortex. J Immunol. 1991;146(2):431\u20137.","journal-title":"J Immunol"},{"issue":"4","key":"245_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"N Garcon","year":"2011","unstructured":"Garcon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10(4):471\u201386.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"245_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16(1):55\u201363.","journal-title":"Expert Rev Vaccines"},{"key":"245_CR16","unstructured":"Official-Journal-of-the-European-Union. L119. 2016; Available from: http:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/HTML\/?uri=CELEX:32016R0679&from=EN ."},{"issue":"12","key":"245_CR17","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1128\/IAI.01804-06","volume":"75","author":"BW Faber","year":"2007","unstructured":"Faber BW, et al. Malaria vaccine-related benefits of a single protein comprising plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun. 2007;75(12):5947\u201355.","journal-title":"Infect Immun"},{"issue":"12","key":"245_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003960","volume":"3","author":"M Roestenberg","year":"2008","unstructured":"Roestenberg M, et al. Safety and immunogenicity of a recombinant plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One. 2008;3(12):e3960.","journal-title":"PLoS One"},{"key":"245_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-4939-6445-1_5","volume":"1494","author":"L Brunner","year":"2017","unstructured":"Brunner L, Barnier-Quer C, Collin N. QS-21 adjuvant: laboratory-scale purification method and formulation into Liposomes. Methods Mol Biol. 2017;1494:73\u201386.","journal-title":"Methods Mol Biol"},{"key":"245_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-60761-585-9_6","volume":"626","author":"J Haensler","year":"2010","unstructured":"Haensler J. Liposomal adjuvants: preparation and formulation with antigens. Methods Mol Biol. 2010;626:73\u201390.","journal-title":"Methods Mol Biol"},{"key":"245_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/978-1-4615-1971-3_116","volume":"378","author":"G Muller","year":"1995","unstructured":"Muller G, et al. Human keratinocyte-derived IL-12 affects LC-induced allogeneic T-cell responses. Adv Exp Med Biol. 1995;378:519\u201321.","journal-title":"Adv Exp Med Biol"},{"issue":"27","key":"245_CR22","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1016\/j.vaccine.2014.04.018","volume":"32","author":"Y Kashiwagi","year":"2014","unstructured":"Kashiwagi Y, et al. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine. 2014;32(27):3393\u2013401.","journal-title":"Vaccine"},{"key":"245_CR23","volume-title":"Manual for the production and control of vaccines : pertussis vaccine","author":"O World Health","year":"1977","unstructured":"World Health O. Manual for the production and control of vaccines : pertussis vaccine. Geneva: World Health Organization; 1977."},{"issue":"3","key":"245_CR24","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.4049\/jimmunol.180.3.1451","volume":"180","author":"MC Huaman","year":"2008","unstructured":"Huaman MC, et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol. 2008;180(3):1451\u201361.","journal-title":"J Immunol"},{"key":"245_CR25","volume-title":"Immunobiology : the immune system in health and disease","author":"C Janeway","year":"2005","unstructured":"Janeway C. Immunobiology : the immune system in health and disease. New York: Garland Science; 2005."},{"issue":"2","key":"245_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.actatropica.2013.04.002","volume":"127","author":"D Silva","year":"2013","unstructured":"Silva D, et al. A whole blood assay as a simple, broad assessment of cytokines and chemokines to evaluate human immune responses to mycobacterium tuberculosis antigens. Acta Trop. 2013;127(2):75\u201381.","journal-title":"Acta Trop"},{"issue":"9","key":"245_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2174\/0929866521666140418100743","volume":"21","author":"H Pan","year":"2014","unstructured":"Pan H, et al. A surfactin lipopeptide adjuvanted hepatitis B vaccines elicit enhanced humoral and cellular immune responses in mice. Protein Pept Lett. 2014;21(9):901\u201310.","journal-title":"Protein Pept Lett"},{"issue":"3","key":"245_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/cmi.2012.2","volume":"9","author":"R Ito","year":"2012","unstructured":"Ito R, et al. Current advances in humanized mouse models. Cell Mol Immunol. 2012;9(3):208\u201314.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"245_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MED.0b013e328337282f","volume":"17","author":"MA Brehm","year":"2010","unstructured":"Brehm MA, Shultz LD, Greiner DL. Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):120\u20135.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"245_CR30","doi-asserted-by":"publisher","first-page":"39097","DOI":"10.1038\/srep39097","volume":"6","author":"TA Olafsdottir","year":"2016","unstructured":"Olafsdottir TA, et al. Comparative systems analyses reveal molecular signatures of clinically tested vaccine Adjuvants. Sci Rep. 2016;6:39097.","journal-title":"Sci Rep"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-018-0245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:43:03Z","timestamp":1693510983000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-018-0245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/s12865-018-0245-0","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"24 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SYY, VS, NW, CK and ER are employees of Biomedical Primate Research Centre, The Netherlands. CB, SH, LB and NC are employees of the Vaccine Formulation Laboratory, University of Lausanne, Switzerland. PD is self-employed. MF is an employee of WHO, Switzerland.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"All animal work was performed under the guidelines of Biomedical Primate Research Centre (BPRC) which uses protocols conforming to European animal welfare regulations. The independent ethics committee at BPRC, constituted according to Dutch law on animal experiments, approved the study protocol (number DEC 658) prior to start of the experiment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing financial interests. SYY, VS, NW, CK and ER are employees of Biomedical Primate Research Centre, The Netherlands. CB, SH, LB and NC are employees of the Vaccine Formulation Laboratory, University of Lausanne, Switzerland. PD is self-employed. MF is an employee of WHO, Switzerland.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}